No data available.
Please log in to see this content.
You have no subscription access to this content.
The full text of this article is not currently available.
Gemcitabine Plus Cisplatin(GC): A Salvage Regimen for Advanced Breast Cancer Patients Who Have Failed Anthracycline and/or Taxane Therapy
Rent:
Rent this article for
JPY
Abstract
Background:In clinical studies of both heavily and minimally pretreated patients with advanced breast cancer,the combination of Gemcitabine plus cisplatin(GC),given in a variety of schedules and doses,has demonstrated moderate safety and efficacy in both heavily and minimally pretreated advanced breast cancer with response rate from 29-63%(median 46%).Methods:We evaluated the activity and toxicity of another GC regimen(gemcitabine 1,000 mg/m2 days 1,8 plus cisplatin 75 mg/m2 day 1 every 3 weeks)in 30 breast cancer patients who failed chemotherapy with anthracycline and/or taxanes as adjuvant or neoadjuvant, or primary therapy. Results:We obtained overall response in 15 of 29 evaluable patients(52%), with responses occurring in all subgroups of disease(unresectable locally advanced, locoregional recurrence, and distant metastasis).Toxicity was primarily hematologic, with grade 3/4 neutropenia and thrombocytopenia in 37% and 17% of patients, respectively. The only grade 3/4 non-hematologic toxicity was grade 3 nausea/vomiting in 12% of patients. Conclusion:Our data suggest that gemcitabine plus cisplatin appears to be effective and has an acceptable toxicity profile in anthracycline and/or taxane pretreated patients with advanced breast cancer.
Full text loading...
/content/article/0385-0684/33060/761